Mikkael Sekeres, MD from the Sylvester Comprehensive Cancer Center discusses data from a phase II study comparing pevonedistat plus azacitidine vs azacitidine alone in higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous leukemia (LB AML).
Data from this study was presented at ASCO 2020. As Dr. Sekeres explains, the safety profiles were similar in the two patient groups. Dr. Sekeres also noted that while the study was not powered to show improvement in overall survival, the combination therapy did show non-significant improvements in event-free survival and overall survival.
For more information about myelodysplastic syndromes, CMML, AML, and other rare hematologic disorders, visit https://checkrare.com/diseases/hematologic-disorders/